Belite Bio Raises $15M to Accelerate Tinlarebant's Clinical Development for Untreatable Eye Diseases

Belite Bio (NASDAQ: BLTE), a San Diego–based clinical stage drug development company, is thrilled to announce a successful funding round that raised $15,000,000. This capital infusion represents a significant milestone for the company, which is dedicated to making a profound impact on patients with untreatable eye diseases such as dry age-related macular degeneration (AMD) and Stargardt disease (STGD1), the most common inherited retinal dystrophy, as well as certain metabolic diseases. The new funds will primarily support the continued development and refinement of Belite Bio's lead pipeline asset, Tinlarebant (also known as LBS-008), a novel oral once-a-day tablet engineered to treat dry AMD and STGD1 at early stages of disease progression. With Tinlarebant currently advancing through a pivotal Phase 3 trial, the fresh capital will be strategically allocated to accelerate clinical development, strengthen operational capabilities, and support an expanded clinical trial footprint. Furthermore, the funding will help enhance regulatory engagement initiatives, given Tinlarebant’s Fast Track and Rare Pediatric Disease (RPD) designations in the United States and its Orphan Drug Designation (ODD) in both the U.S. and the European Medicines Agency (EMA) for STGD1. These regulatory milestones not only underscore the potential impact of Tinlarebant on patient lives but also bolster Belite Bio’s strategic position in the global ophthalmology market. As the company charts its path toward transforming the treatment landscape for these debilitating diseases, Belite Bio remains committed to advancing groundbreaking therapies that promise better outcomes for patients worldwide.